Moreover, ANGPTL3 is already being utilized as a target; the Food and Drug Administration (FDA) has recently approved Evinacumab, a monoclonal antibody against ANGPTL3, as a lipid-lowering agent for individuals with familial hypercholesterolemia (63). The gene discussed is ANGPTL3; the disease is familial hypercholesterolemia.